Results 231 to 240 of about 96,147 (311)

Cardiopulmonary changes and its association with clinical features in noncirrhotic portal hypertension. [PDF]

World J Gastroenterol
Gopalakrishna H, Nguyen ML, Mironova M, Viana Rodriguez GM, Afruza R, Chakraborty M, Menkart MG, Oringher JL, Scott S, Nair GB, Kleiner DE, Koh C, Fallon M, Sachdev V, Heller T.   +14 more
europepmc   +1 more source

Prediction of Hepatocellular Carcinoma and Other Liver‐Related Events in Chronic Hepatitis B Patients With Metabolic Dysfunction or Metabolic Dysfunction‐Associated Steatotic Liver Disease

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 3, Page 374-382, February 2026.
This study evaluated the performance of the PAGE‐B score in HCC risk among CHB patients with metabolic dysfunction or MASLD. The PAGE‐B score effectively stratified HCC risk in both MASLD and non‐MASLD patients, especially in those without cirrhosis, where low scores were linked to negligible 5‐year HCC risk. ABSTRACT Introduction Metabolic dysfunction
Lesley A. Patmore, Ivana Carey, Jordan J. Feld, Willem P. Brouwer, Keyur Patel, Maria Buti, Pieter Honkoop, Douwe F. Postma, Hans Blokzijl, Özgur. M. Koc, Eva van Oorschot, Kosh Agarwal, Marc van der Valk, Faydra I. Lieveld, Mai Kilany, Matthijs Kramer, Joep de Bruijne, Mark A. A. Claassen, Bettina E. Hansen, Robert A. de Man, Harry L. A. Janssen, R. Bart Takkenberg, Milan J. Sonneveld   +22 more
wiley   +1 more source

Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 4, Page 494-506, February 2026.
In a multi‐centre study of obeticholic acid in primary biliary cholangitis, 45% discontinued the drug over 4 years, with 11% moving to combination therapy (fibrates). Of those continuing, response rates increased from 37% (1 year) to 55% (4 years). Non‐response at 12 months and cirrhosis were independent predictors of liver‐related events.
Nadir Abbas, Rachel Smith, Ellina Lytvyak, Miki Scaravaglio, Neil Halliday, Amal Almahroos, Nadia Eden, Diane Lloyd‐Madden, Sanchit Sharma, James Ferguson, Jessica K. Dyson, Douglas Thorburn, David Jones, Aldo J. Montano‐Loza, Marco Carbone, Pietro Invernizzi, George Mells, Emma L. Culver, Palak J. Trivedi   +18 more
wiley   +1 more source

Experimental Portal Hypertension

Annals of Surgery, 1957
openaire   +3 more sources

Research Communication: The Cumulated Spontaneous Portosystemic Shunts (SPSS) Area Decreases After TIPS and Impacts on Prognosis

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 3, Page 419-423, February 2026.
This study shows that both the total SPSS area and the cumulative SPSS diameter decrease significantly and persistently after TIPS placement, whereas the total shunt diameter increases slightly and the total shunt area remains stable. The relative change in SPSS area serves as an independent predictor of mortality. ABSTRACT We evaluated the dynamics of
Marlene Hintersteininger, Theresa Müllner‐Bucsics, Susanna Riegler, Nina Dominik, Georg Kramer, Christian Sebesta, Paul Thöne, Ulrika Asenbaum, Lukas Reider, Maria Schoder, Michael Trauner, Mattias Mandorfer, Thomas Reiberger, Lukas Hartl, Katharina Lampichler   +14 more
wiley   +1 more source

Severe Bleeding From Portal Hypertension in a Young Patient With Common Variable Immunodeficiency-Associated Nodular Regenerative Hyperplasia. [PDF]

ACG Case Rep J
Kamalumpundi V, Daher D, Chen ZE, Khan S, Chowla N.   +4 more
europepmc   +1 more source

Alterations in Gut Microbiota and Metabolism in Cirrhotic Portal Hypertension: Implications for Disease Progression

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 4, Page 538-556, February 2026.
In‐depth multiomics analyses revealed that the gut microbiota in patients with CPH is dysbiotic. Altered gut microbiota plays an important role in the progression of CPH and affects the host's arginine metabolism to promote arginine biosynthesis. The pro‐inflammatory effects of certain gut bacteria induce iNOS expression, which together act on the ...
Qun Zhang, Jinghua Cui, Yixin Hou, Lining Guo, Hai Li, Guiqin Zhou, Xiaojing Wang, Bingbing Zhu, Ke Shi, Yi Zhang, Yufei Bi, Yanqiu Li, Lina Sun, Ying Feng, Jing Yuan, Xianbo Wang   +15 more
wiley   +1 more source

Usefulness of A Portal Vein Stent for Sinistral Portal Hypertension: A Case Report. [PDF]

Surg Case Rep
Takimoto D, Ishida J, Toyama H, Nanno Y, Mizumoto T, Yoshida T, Urade T, Fukushima K, Gon H, Tsugawa D, Komatsu S, Yanagimoto H, Kido M, Fukumoto T.   +13 more
europepmc   +1 more source

RNA Analysis Uncovers Pathogenic PARN Variant in Dyskeratosis Congenita

Clinical Genetics, Volume 109, Issue 2, Page 346-351, February 2026.
Using WGS and RNA analysis, we identified a branch point‐disrupting variant in the PARN gene and elucidated its pathogenic molecular mechanism in a child with atypical dyskeratosis congenita presentation. ABSTRACT Dyskeratosis congenita (DC) is a rare genetic disorder caused by impaired telomere maintenance, leading to diverse clinical manifestations ...
Daria Akimova, Natalia Semenova, Tatiana Cherevatova, Mikhail Skoblov   +3 more
wiley   +1 more source

Revolutionising portal hypertension diagnosis: the rise of non-invasive techniques in liver cirrhosis. [PDF]

Front Med (Lausanne)
Gao B, Lin Y, Zhang H, Li Y, Gou S, Ma P, Zhao X, Zhou Y, Chen Q, Yuan L, Han Z, Yu C.   +11 more
europepmc   +1 more source